| | |
每股
|
| |
總計
|
| ||||||
公開發行價
|
| | | $ | 8.00 | | | | | $ | 22,400,000 | | |
承保折扣和佣金(1)
|
| | | $ | 0.56 | | | | | $ | 1,568,000 | | |
扣除費用前的收益,付給我們
|
| | | $ | 7.44 | | | | | $ | 20,832,000 | | |
| | |
頁面
|
| |||
| | | | 1 | | | |
| | | | 14 | | | |
| | | | 72 | | | |
| | | | 73 | | | |
| | | | 75 | | | |
| | | | 76 | | | |
| | | | 78 | | | |
| | | | 81 | | | |
| | | | 82 | | | |
| | | | 99 | | | |
| | | | 153 | | | |
| | | | 163 | | | |
| | | | 174 | | | |
| | | | 178 | | | |
| | | | 182 | | | |
| | | | 189 | | | |
| | | | 192 | | | |
| | | | 196 | | | |
| | | | 205 | | | |
| | | | 205 | | | |
| | | | 205 | | | |
| | | | F-1 | | |
| | |
截至的年度
12月31日, |
| |
截至三個月
3月31日, |
| ||||||||||||||||||
| | |
2022
|
| |
2023
|
| |
2023
|
| |
2024
|
| ||||||||||||
| | | | | | | | | | | | | | |
(未經審計)
|
| |||||||||
合併業務報表: | | | | | | | | | | | | | | | | | | | | | | | | | |
運營費用: | | | | | | | | | | | | | | | | | | | | | | | | | |
研發
|
| | | $ | 16,387,216 | | | | | $ | 21,708,332 | | | | | $ | 4,523,757 | | | | | $ | 6,860,430 | | |
一般和行政
|
| | | | 3,819,591 | | | | | | 3,265,497 | | | | | | 774,799 | | | | | | 912,824 | | |
總運營費用
|
| | | | 20,206,807 | | | | | | 24,973,829 | | | | | | 5,298,556 | | | | | | 7,773,254 | | |
運營虧損
|
| | | | (20,206,807) | | | | | | (24,973,829) | | | | | | (5,298,556) | | | | | | (7,773,254) | | |
其他收入(支出): | | | | | | | | | | | | | | | | | | | | | | | | | |
認股權證負債的公允價值變動
|
| | | | 36,579 | | | | | | (79,822) | | | | | | 5,104 | | | | | | (32,515) | | |
發行按公允價值應付的關聯方可轉換票據損失
|
| | | | — | | | | | | — | | | | | | — | | | | | | (200,000) | | |
應付關聯方可轉換票據估計公允價值變化
|
| | | | — | | | | | | — | | | | | | — | | | | | | (300,000) | | |
利息支出
|
| | | | (16,200) | | | | | | (43,641) | | | | | | (28,454) | | | | | | (5,076) | | |
利息收入
|
| | | | 27,027 | | | | | | 352,672 | | | | | | 51,651 | | | | | | 14,786 | | |
其他收入(費用)合計,淨額
|
| | | | 47,406 | | | | | | 229,209 | | | | | | 28,301 | | | | | | (522,805) | | |
淨虧損
|
| | | $ | (20,159,401) | | | | | $ | (24,744,620) | | | | | $ | (5,270,255) | | | | | $ | (8,296,059) | | |
普通股股東應占每股基本虧損和稀釋後每股淨虧損
|
| | | $ | (16.65) | | | | | $ | (17.24) | | | | | $ | (3.93) | | | | | $ | (5.40) | | |
加權平均普通股流通股、基本普通股和稀釋普通股 (1)
|
| | | | 1,210,629 | | | | | | 1,434,964 | | | | | | 1,339,729 | | | | | | 1,535,167 | | |
預計每股基本和攤薄淨虧損(未經審計) (2)
|
| | | | | | | | | $ | (1.65) | | | | | | | | | | | $ | (0.54) | | |
預計加權平均已發行普通股、基本普通股和攤薄普通股(未經審計) (2)
|
| | | | | | | | | | 15,033,731 | | | | | | | | | | | | 15,489,551 | | |
| | |
截至2024年3月31日
|
| |||||||||||||||
| | |
實際
|
| |
形式上(1)
|
| |
形式上的作爲
調整後的(2) |
| |||||||||
| | | | | | | | |
(未經審計)
|
| |||||||||
綜合資產負債表數據: | | | | | | | | | | | | | | | | | | | |
現金及現金等價物
|
| | | $ | 2,068,307 | | | | | $ | 3,068,307 | | | | | $ | 22,235,307 | | |
營運資本(赤字)(3)
|
| | | | (12,545,792) | | | | | | (6,545,792) | | | | | | 12,621,208 | | |
總資產
|
| | | | 2,698,583 | | | | | | 3,698,583 | | | | | | 22,865,583 | | |
總負債
|
| | | | 16,294,545 | | | | | | 10,273,981 | | | | | | 10,273,981 | | |
可贖回可轉換優先股
|
| | | | 94,178,404 | | | | | | — | | | | | | — | | |
股東(赤字)權益總額
|
| | | $ | (107,774,366) | | | | | $ | (6,575,398) | | | | | $ | 12,591,602 | | |
| | |
截至2024年3月31日
|
| |||||||||||||||
| | |
實際
|
| |
形式上
|
| |
形式上的作爲
調整後的 |
| |||||||||
| | | | | | | | |
(未經審計)
|
| |||||||||
現金及現金等價物
|
| |
2,068,307美元
|
| |
3,068,307美元
|
| |
22,235,307美元
|
| |||||||||
按公允價值應付的關聯方可轉換票據
|
| | | $ | 5,000,000 | | | | | $ | — | | | | | $ | — | | |
可贖回可轉換優先股認股權證負債
|
| | | | 1,020,564 | | | | | | — | | | | | | — | | |
可贖回可轉換優先股,面值0.00001美元; 33,463,018股授權股份,24,678,355股已發行和發行的股份,實際;沒有授權、已發行或發行的股份,形式和形式調整
|
| | | | 94,178,404 | | | | | | — | | | | | | — | | |
股東(虧損)權益:
|
| | | | | | | | | | | | | | | | | | |
普通股,面值0.00001美元; 38,108,584股
授權,已發行和發行1,690,760股, 實際; 38,108,584股授權股,16,311,636股 已發行和發行的股票,形式; 授權股200,000,000股,19,111,636股 已發行和未償還,經調整的形式 |
| | | | 3 | | | | | | 16 | | | | | | 19 | | |
額外實收資本
|
| | | | 5,616,211 | | | | | | 106,815,166 | | | | | | 125,982,163 | | |
累計赤字
|
| | | | (113,390,580) | | | | | | (113,390,580) | | | | | | (113,390,580) | | |
股東(赤字)權益總額
|
| | | $ | (107,774,366) | | | | | $ | (6,575,398) | | | | | $ | 12,591,602 | | |
總市值
|
| | | $ | (7,575,398) | | | | | $ | (6,575,398) | | | | | $ | 12,591,602 | | |
|
普通股每股首次公開發行價格
|
| | | | | | | | | $ | 8.00 | | |
|
截至2024年3月31日每股歷史有形淨賬面價值(虧損)
|
| | | $ | (63.74) | | | | | | | | |
|
截至2024年3月31日每股歷史有形淨價值預計增加
歸因於上述形式調整 |
| | | | 63.34 | | | | | | | | |
|
截至2024年3月31日的每股預計有形淨現值
|
| | | | (0.40) | | | | | | | | |
|
參與本次發行的新投資者應占的調整後每股有形淨淨資產增加
|
| | | | 1.06 | | | | | | | | |
|
預計本次發行後調整後的每股有形賬面淨值
|
| | | | | | | | | | 0.66 | | |
|
對參與此次發行的新投資者的每股攤薄
|
| | | | | | | | | $ | 7.34 | | |
| | |
股份
購得 |
| |
總
考慮事項 |
| |
加權的-
平均價格 |
| |||||||||||||||||||||
| | |
Number
|
| |
百分比
|
| |
金額
|
| |
百分比
|
| |
每股
|
| |||||||||||||||
此次發行前的現有股東
|
| | | | 16,311,636 | | | | | | 85.3% | | | | | $ | 101,033,615 | | | | | | 81.85% | | | | | $ | 6.19 | | |
投資者在此次發行中購買證券
|
| | | | 2,800,000 | | | | | | 14.7% | | | | | $ | 22,400,000 | | | | | | 18.15% | | | | | $ | 8.00 | | |
總計
|
| | | | 19,111,636 | | | | | | 100.0% | | | | | $ | 123,433,615 | | | | | | 100.0% | | | | | $ | 6.46 | | |
| | |
截至三個月
3月31日, |
| | | | | | | |||||||||
| | |
2024
|
| |
2023
|
| |
變化
|
| |||||||||
| | |
(未經審計)
|
| | | | | | | |||||||||
運營費用: | | | | | | | | | | | | | | | | | | | |
研發
|
| | | $ | 6,860,430 | | | | | $ | 4,523,757 | | | | | $ | 2,336,673 | | |
一般和行政
|
| | | | 912,824 | | | | | | 774,799 | | | | | | 138,025 | | |
總運營費用
|
| | | | 7,773,254 | | | | | | 5,298,556 | | | | | | 2,474,698 | | |
運營虧損
|
| | | | (7,773,254) | | | | | | (5,298,556) | | | | | | (2,474,698) | | |
其他收入(支出): | | | | | | | | | | | | | | | | | | | |
認股權證負債的公允價值變動
|
| | | | (32,515) | | | | | | 5,104 | | | | | | (37,619) | | |
發行關聯方可轉換票據的損失應付日期
公允價值 |
| | | | (200,000) | | | | | | — | | | | | | (200,000) | | |
應付關聯方可轉換票據估計公允價值變化
|
| | | | (300,000) | | | | | | — | | | | | | (300,000) | | |
利息支出
|
| | | | (5,076) | | | | | | (28,454) | | | | | | 23,378 | | |
利息收入
|
| | | | 14,786 | | | | | | 51,651 | | | | | | (36,865) | | |
其他收入(費用)合計,淨額
|
| | | | (522,805) | | | | | | 28,301 | | | | | | (551,106) | | |
淨虧損
|
| | | $ | (8,296,059) | | | | | $ | (5,270,255) | | | | | | (3,025,804) | | |
| | |
截至三個月
3月31日, |
| | | | | | | |||||||||
| | |
2024
|
| |
2023
|
| |
變化
|
| |||||||||
外部臨床試驗費用
|
| | | $ | 5,098,162 | | | | | $ | 2,581,882 | | | | | $ | 2,516,280 | | |
人員和諮詢費用
|
| | | | 868,974 | | | | | | 1,044,081 | | | | | | (175,107) | | |
臨床前和生物標誌物研究
|
| | | | 304,788 | | | | | | 86,961 | | | | | | 217,827 | | |
MCC相關費用
|
| | | | 588,506 | | | | | | 810,833 | | | | | | (222,327) | | |
研發費用總額
|
| | | $ | 6,860,430 | | | | | $ | 4,523,757 | | | | | $ | 2,336,673 | | |
| | |
截至三個月
3月31日, |
| | | | | | | |||||||||
| | |
2024
|
| |
2023
|
| |
變化
|
| |||||||||
員工有關連的開支
|
| | | $ | 400,300 | | | | | $ | 478,969 | | | | | $ | (78,669) | | |
專業和諮詢費
|
| | | | 500,356 | | | | | | 200,290 | | | | | | 300,066 | | |
其他費用
|
| | | | 12,168 | | | | | | 95,540 | | | | | | (83,372) | | |
一般和行政費用總額
|
| | | $ | 912,824 | | | | | $ | 774,799 | | | | | $ | 138,025 | | |
| | |
可贖回
敞篷車 優先股 認股權證法律責任 |
| |||
截至2022年12月31日的公允價值
|
| | | $ | 814,364 | | |
公允價值變動
|
| | | | (5,104) | | |
截至2023年3月31日的公允價值
|
| | | $ | 809,260 | | |
截至2023年12月31日的公允價值
|
| | | | 988,049 | | |
公允價值變動
|
| | | | 32,515 | | |
截至2024年3月31日的公允價值
|
| | | $ | 1,020,564 | | |
| | |
截至2013年12月31日止的年度,
|
| | | | | | | |||||||||
| | |
2023
|
| |
2022
|
| |
變化
|
| |||||||||
運營費用: | | | | | | | | | | | | | | | | | | | |
研發
|
| | | $ | 21,708,332 | | | | | $ | 16,387,216 | | | | | $ | 5,321,116 | | |
一般和行政
|
| | | | 3,265,497 | | | | | | 3,819,591 | | | | | | (554,094) | | |
總運營費用
|
| | | | 24,973,829 | | | | | | 20,206,807 | | | | | | 4,767,022 | | |
運營虧損
|
| | | | (24,973,829) | | | | | | (20,206,807) | | | | | | (4,767,022) | | |
其他收入(支出): | | | | | | | | | | | | | | | | | | | |
認股權證負債的公允價值變動
|
| | | | (79,822) | | | | | | 36,579 | | | | | | (116,401) | | |
利息支出
|
| | | | (43,641) | | | | | | (16,200) | | | | | | (27,441) | | |
利息收入
|
| | | | 352,672 | | | | | | 27,027 | | | | | | 325,645 | | |
其他收入合計,淨額
|
| | | | 229,209 | | | | | | 47,406 | | | | | | 181,803 | | |
淨虧損
|
| | | $ | (24,744,620) | | | | | $ | (20,159,401) | | | | | $ | (4,585,219) | | |
| | |
截至2013年12月31日止的年度,
|
| | | | | | | |||||||||
| | |
2023
|
| |
2022
|
| |
變化
|
| |||||||||
外部臨床試驗費用
|
| | | $ | 13,986,355 | | | | | $ | 10,513,275 | | | | | $ | 3,473,080 | | |
人員和諮詢費用
|
| | | | 3,675,373 | | | | | | 2,028,258 | | | | | | 1,647,115 | | |
臨床前和生物標誌物研究
|
| | | | 1,800,324 | | | | | | 1,934,217 | | | | | | (133,893) | | |
MCC相關費用
|
| | | | 2,246,280 | | | | | | 1,911,466 | | | | | | 334,814 | | |
研發費用總額
|
| | | $ | 21,708,332 | | | | | $ | 16,387,216 | | | | | $ | 5,321,116 | | |
| | |
截至2013年12月31日止的年度,
|
| | | | | | | |||||||||
| | |
2023
|
| |
2022
|
| |
變化
|
| |||||||||
員工有關連的開支
|
| | | $ | 1,827,250 | | | | | $ | 2,579,222 | | | | | $ | (751,972) | | |
專業和諮詢費
|
| | | | 1,083,243 | | | | | | 945,845 | | | | | | 137,398 | | |
其他費用
|
| | | | 355,004 | | | | | | 294,524 | | | | | | 60,480 | | |
一般和行政費用總額
|
| | | $ | 3,265,497 | | | | | $ | 3,819,591 | | | | | $ | (554,094) | | |
| | |
可贖回
敞篷車 優先股 認股權證法律責任 |
| |||
截至2022年1月1日的公允價值
|
| | | $ | 850,943 | | |
公允價值變動
|
| | | | (36,579) | | |
截至2022年12月31日的公允價值
|
| | | | 814,364 | | |
與發行可贖回可轉換優先股相關向配股代理發行的認購證的估計公平市場價值
|
| | | | 93,863 | | |
公允價值變動
|
| | | | 79,822 | | |
截至2023年12月31日的公允價值
|
| | | $ | 988,049 | | |
| | |
截至三個月
3月31日, |
| |||||||||
| | |
2024
|
| |
2023
|
| ||||||
用於經營活動的現金淨額
|
| | | $ | (5,247,582) | | | | | $ | (5,358,841) | | |
融資活動提供的現金淨額
|
| | | | 4,357,230 | | | | | | 2,463,431 | | |
現金和現金等價物淨變化
|
| | | $ | (890,352) | | | | | $ | (2,895,410) | | |
| | |
截至2013年12月31日止的年度,
|
| |||||||||
| | |
2023
|
| |
2022
|
| ||||||
用於經營活動的現金淨額
|
| | | $ | (21,625,167) | | | | | $ | (17,794,093) | | |
融資活動提供的現金淨額
|
| | | | 4,134,516 | | | | | | 19,255,569 | | |
現金和現金等價物淨變化
|
| | | $ | (17,490,651) | | | | | $ | 1,461,476 | | |
組織學
|
| |
數量
受試者(n) |
| |
平均數
先前的治療線 (範圍) |
|
成釉細胞瘤
|
| |
1
|
| |
0
|
|
肛門
|
| |
1
|
| |
3 (3)
|
|
附錄
|
| |
4
|
| |
1 (1 – 2)
|
|
膽管
|
| |
1
|
| |
4 (4)
|
|
氯化萘
|
| |
4
|
| |
0 (0 – 1)
|
|
結直腸
|
| |
14
|
| |
5 (0 – 13)
|
|
子宮內膜
|
| |
1
|
| |
0 (0)
|
|
食管
|
| |
2
|
| |
4 (3 – 5)
|
|
頭頸
|
| |
1
|
| |
3 (3)
|
|
腎
|
| |
2
|
| |
2 (0 – 3)
|
|
白血病
|
| |
1
|
| |
0 (0)
|
|
肝
|
| |
1
|
| |
7 (7)
|
|
肺
|
| |
4
|
| |
2 (2 – 3)
|
|
淋巴瘤
|
| |
2
|
| |
2 (0 – 3)
|
|
黑素瘤
|
| |
13
|
| |
3 (0 – 6)
|
|
其他
|
| |
1
|
| |
0 (0)
|
|
胰腺
|
| |
7
|
| |
2 (0 – 7)
|
|
前列腺
|
| |
2
|
| |
9 (8 – 9)
|
|
肉瘤
|
| |
2
|
| |
6 (4 – 8)
|
|
皮膚,非黑色素瘤
|
| |
1
|
| |
1 (1)
|
|
子宮
|
| |
2
|
| |
6 (4 – 7)
|
|
| | |
按Elraglusib劑量水平列出的患者數量(%)(毫克/公斤)
|
| | ||||||||||||||||||||||||||||||||||||||
腫瘤類型
|
| |
3.3
(N=21) |
| |
5.0
(N=39) |
| |
7.0
(N=38) |
| |
9.3
(N=11) |
| |
12.4
(N=2) |
| |
15.0
(N=60) |
| |
總
(N=171) |
| |||||||||||||||||||||
腎上腺
|
| | | | 0 | | | | | | 1 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 1 | | |
間變性少突
|
| | | | 0 | | | | | | 1 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 1 | | |
細胞瘤
|
| | | | 0 | | | | | | 1 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 1 | | |
膽道
|
| | | | 0 | | | | | | 1 | | | | | | 1 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 2 | | |
乳腺
|
| | | | 3 | | | | | | 2 | | | | | | 2 | | | | | | 0 | | | | | | 1 | | | | | | 0 | | | | | | 8 | | |
宮頸/子宮/子宮內膜
|
| | | | 0 | | | | | | 1 | | | | | | 2 | | | | | | 1 | | | | | | 0 | | | | | | 3 | | | | | | 7 | | |
氯化萘
|
| | | | 1 | | | | | | 3 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 2 | | | | | | 6 | | |
結直腸
|
| | | | 1 | | | | | | 3 | | | | | | 10 | | | | | | 0 | | | | | | 1 | | | | | | 9 | | | | | | 24 | | |
子宮內膜
|
| | | | 0 | | | | | | 0 | | | | | | 1 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 1 | | |
食管
|
| | | | 1 | | | | | | 1 | | | | | | 1 | | | | | | 0 | | | | | | 0 | | | | | | 2 | | | | | | 5 | | |
輸卵管
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 1 | | | | | | 1 | | |
膽囊
|
| | | | 0 | | | | | | 0 | | | | | | 1 | | | | | | 0 | | | | | | 0 | | | | | | 1 | | | | | | 2 | | |
膠質瘤
|
| | | | 0 | | | | | | 1 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 4 | | | | | | 5 | | |
膠質肉瘤
|
| | | | 0 | | | | | | 1 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 1 | | |
H&N
|
| | | | 1 | | | | | | 2 | | | | | | 1 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 4 | | |
| | |
按Elraglusib劑量水平列出的患者數量(%)(毫克/公斤)
|
| | ||||||||||||||||||||||||||||||||||||||
腫瘤類型
|
| |
3.3
(N=21) |
| |
5.0
(N=39) |
| |
7.0
(N=38) |
| |
9.3
(N=11) |
| |
12.4
(N=2) |
| |
15.0
(N=60) |
| |
總
(N=171) |
| |||||||||||||||||||||
脂肪肉瘤
|
| | | | 0 | | | | | | 0 | | | | | | 1 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 1 | | |
肝
|
| | | | 0 | | | | | | 1 | | | | | | 0 | | | | | | 1 | | | | | | 0 | | | | | | 3 | | | | | | 5 | | |
肺
|
| | | | 1 | | | | | | 2 | | | | | | 4 | | | | | | 2 | | | | | | 0 | | | | | | 2 | | | | | | 11 | | |
黑素瘤
|
| | | | 1 | | | | | | 1 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 2 | | |
梅克爾細胞
|
| | | | 1 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 1 | | |
間皮瘤
|
| | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 2 | | | | | | 2 | | |
其他
|
| | | | 0 | | | | | | 1 | | | | | | 1 | | | | | | 1 | | | | | | 0 | | | | | | 0 | | | | | | 3 | | |
卵巢
|
| | | | 2 | | | | | | 0 | | | | | | 1 | | | | | | 2 | | | | | | 0 | | | | | | 5 | | | | | | 10 | | |
胰腺
|
| | | | 7 | | | | | | 16 | | | | | | 12 | | | | | | 4 | | | | | | 0 | | | | | | 19 | | | | | | 58 | | |
肉瘤
|
| | | | 1 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 6 | | | | | | 7 | | |
未知
|
| | | | 1 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 0 | | | | | | 1 | | | | | | 2 | | |
結果
|
| |
Elralusib單一療法
第1部分(N=62) |
| |
埃拉魯西布伴化療
第2部分(N=138) |
|
操作系統,中位數(95%CI),月份(A)
|
| |
7.7 (5.1, 9.7)
|
| |
6.9 (5.7, 8.4)
|
|
無生命週期,中位數(95%CI),月(A)
|
| |
1.6 (1.3, 2.2)
|
| |
2.1 (2.0, 2.6)
|
|
最佳總體反應,n(%) | | | | | | | |
完全緩解
|
| |
1 (1.6)
|
| |
0 (0.0)
|
|
部分緩解
|
| |
1 (1.6)
|
| |
7 (5.1)
|
|
疾病穩定
|
| |
24 (38.7)
|
| |
57 (41.3)
|
|
進行性疾病
|
| |
30 (48.4)
|
| |
70 (50.7)
|
|
未報告
|
| |
6 (9.7)
|
| |
4 (2.9)
|
|
化療支柱/癌症類型
|
| |
mPPC(月)
|
| |
mOS(月)
|
|
阿黴素(N=10)
肉瘤-5
卵巢-2 乳房-1 腎上腺-1 食道-1 |
| | 2.4 | | | 10.4 | |
伊立替康(N=34)
結直腸-20
胰腺-11 胃-2 膽囊-1 |
| | 2.1 | | | 6.9 | |
任何卡鉑組(N=50)
肺-10
卵巢-7 食道-4 頭部和頸部-4 子宮-3 肝臟-3 結直腸-3 乳房-2 Ceremic- 2 子宮內膜-2 間皮瘤-2 未知-2 黑色素瘤-2 膽囊-1 默克爾細胞-1 胰腺-1 管子-1 |
| | 2.1 | | | 7.6 | |
GnP(N=27)
胰腺-26
骨肉瘤-1 |
| | 3.1 | | | 5.6 | |
洛莫司汀(N=14)
中樞神經系統6
膠質母細胞瘤-5 星形細胞瘤-1 膠質肉瘤-1 間變性少突膠質瘤-1 |
| | 5.3 | | | 11.4 | |
響應
|
| |
EE人群
(N=29) |
|
CR,n(%)
|
| |
2 (6.9)
|
|
PR,n(%)
|
| |
9 (31)
|
|
SD ' 16周,n(%)
|
| |
4 (13.8)
|
|
SD <16周,n(%)
|
| |
11 (37.9)
|
|
疾病進展,n(%)
|
| |
3 (10.1)
|
|
疾病控制率(CR+PR+SD & 16周),n(%)
|
| |
15 (51.7)
95%CI:(32.5,70.6) |
|
MPFS
|
| |
5.4個月(ITT爲4.9個月)
|
|
MOS
|
| |
15.3個月(11.9個月ITT)
|
|
IND#
|
| |
相位
|
| |
NCt # /贊助商
|
| |
研究標題
|
| |
給藥方案
|
| |
研究人群
|
| |
FVFP(1)
|
| |
計劃
入學 |
| |
數量
患者/ 研究現狀 |
|
156280
|
| |
2
|
| |
NCT 05010629
格倫·J·漢納,醫學博士
|
| |
9-ING-41(一種糖元合酶蛋白酶3 β(GSk 3β)抑制劑聯合鉑治療晚期轉移性唾液腺癌患者的II期研究
|
| |
9-ING-41每週兩次靜脈輸注給藥,與每21天給藥一次卡鉑聯合給藥
|
| |
患有無法治癒、復發或轉移性唾液腺癌的成年人
|
| | 2021年9月 | | |
35例受試者
|
| |
總數:35 /入組完全治療正在進行中
|
|
157852
|
| |
2
|
| |
NCT 05239182
安瓦爾·賽義德,醫學博士
|
| |
一項關於9-ING-41(一種糖元合酶蛋白酶3-β(GSk-3β)抑制劑與Retifanlimab(一種PD-1抑制劑)聯合使用的II期研究/吉西他濱/Nab-紫杉醇作爲晚期胰腺腺癌患者的一線治療方法(RiLEY)
|
| |
9-ING-41每週兩次靜脈輸注,在28天週期的第1、8和15天與GnP聯合給藥,在第1天與retifanlimab聯合給藥。
|
| |
既往未接受過任何晚期疾病系統治療的胰腺癌成年人
|
| | 2022年2月 | | |
32例受試者
|
| | 總數:7 | |
157435
|
| |
2
|
| |
NCT 05077800
科林·D醫學博士威克斯
|
| |
一項FOLFFIRIN諾克斯聯合糖原合酶K-3 β(GSk-3 β)抑制劑9-ING-41和轉化生長因子-β(轉化生長因子-β)抑制劑Losartan治療未經治療的轉移性腺癌患者的II期研究
|
| |
9-ING-41每週靜脈滴注兩次,聯合FOLFIRINOX每14天一次,每日一次氯沙坦
|
| |
成人未經治療的轉移性胰腺癌
|
| | 2022年4月 | | |
70名受試者
|
| |
總數:35/登記和治療正在進行中
|
|
名字
|
| |
年齡
|
| |
職位
|
|
行政人員: | | | | | | | |
Daniel M.施密特 | | | 62 | | |
董事首席執行官總裁
|
|
Andrew P. Mazar,博士 | | | 62 | | | 首席運營官 | |
保羅·萊特爾 | | | 56 | | | 首席財務官 | |
非僱員董事和董事提名人: | | | | | | | |
亞倫·GL弗萊徹博士 | | | 43 | | | 主席和董事(1) | |
小萊斯·克雷斯 | | | 52 | | | 主任(2)(3) | |
託德·湯姆森 | | | 63 | | | 主任(1)(3)(4) | |
丹·扎布洛夫斯基博士。 | | | 64 | | |
主任(1)(3)(5)
|
|
傑森·凱斯 | | | 53 | | |
董事提名者(4)(5)
|
|
羅傑·索尼 | | | 54 | | |
董事提名者(3)(4)(5)
|
|
艾米·羅恩伯格 | | | 50 | | |
董事提名者(3)(4)(5)
|
|
名字
|
| |
年
|
| |
薪金
|
| |
獎金
|
| |
庫存
授獎(1) |
| |
選擇權
獎項(1) |
| |
所有其他
補償 |
| |
總計
|
| |||||||||||||||||||||
Daniel·M·施密特 (2)
總裁與首席執行官 |
| | | | 2023 | | | | | $ | 400,000 | | | | | $ | 120,000 | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | 520,000 | | |
| | | 2022 | | | | | $ | 400,000 | | | | | $ | 44,489 | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | 444,489 | | | ||
安德魯·P·馬扎爾博士 (3)
首席運營官 |
| | | | 2023 | | | | | $ | 450,000 | | | | | $ | 157,500 | | | | | $ | — | | | | | $ | 58,612 | | | | | $ | — | | | | | $ | 666,112 | | |
| | | 2022 | | | | | $ | 377,500 | | | | | $ | 287,544 | | | | | $ | 85,071 | | | | | $ | — | | | | | $ | — | | | | | $ | 750,115 | | |
| | |
期權大獎
|
| |
股票大獎
|
| ||||||||||||||||||||||||||||||||||||||||||||||||
名字
|
| |
授予日期
|
| |
數量
證券 潛在的 未鍛鍊身體 選項 可操練 |
| |
數量
證券 潛在的 未鍛鍊身體 選項 不能行使 |
| |
選擇權
鍛鍊 價格 ($) |
| |
選擇權
期滿 日期 |
| |
數量
股票或 庫存單位 他們有 未歸屬 |
| |
市場
價值 的股份 庫存單位 他們有 未歸屬 |
| |
股權
激勵 計劃獎勵: 數量 不勞而獲 股票, 單位或其他 權利,即 有 未歸屬 |
| |
股權
激勵措施 計劃獎勵: 市場或 派息值 不勞而獲 股份、單位 或其他 權利 那些還沒有 既得(1) |
| |||||||||||||||||||||||||||
Daniel·M·施密特(2)
|
| | | | 2/5/16(3) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 11,727 | | | | | $ | 44,114 | | |
| | | 2/22/21(4) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 107,718 | | | | | $ | 405,234 | | | ||
安德魯·P·馬扎爾博士(2)
|
| | | | 2/22/21(5) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 8,103 | | | | | $ | 30,481 | | |
| | | 7/7/22(6) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 26,089 | | | | | $ | 98,144 | | | ||
| | | 10/23/23(7) | | | | | | — | | | | | | 37,374 | | | | | | 2.142 | | | | | | 10/23/33 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
名字
|
| |
庫存
獎項 |
| |
選擇權
獎項(1) |
| |
所有其他
補償 |
| |
總計
|
| ||||||||||||
艾倫·G·L·弗萊徹博士(2)
|
| | | $ | — | | | | | $ | 23,288 | | | | | $ | — | | | | | $ | 23,288 | | |
小萊斯·克雷斯(2)(3)
|
| | | $ | — | | | | | $ | 23,288 | | | | | $ | — | | | | | $ | 23,288 | | |
託德·湯姆森(4)
|
| | | $ | — | | | | | $ | 23,288 | | | | | $ | — | | | | | $ | 23,288 | | |
丹·扎布洛夫斯基博士。(5)
|
| | | $ | — | | | | | $ | 23,288 | | | | | $ | — | | | | | $ | 23,288 | | |
| | |
金額
|
| |||
年度董事薪酬現金保留者
|
| | | $ | 40,000 | | |
董事會年度主席或首席獨立董事薪酬現金保留人(代替年度董事薪酬現金保留人)
|
| | | $ | 70,000 | | |
委員會主席的額外年薪 | | | | | | | |
審計委員會
|
| | | $ | 19,000 | | |
薪酬委員會
|
| | | $ | 12,000 | | |
提名和公司治理委員會
|
| | | $ | 8,000 | | |
委員會成員(主席除外)的額外年薪 | | | | | | | |
審計委員會
|
| | | $ | 9,000 | | |
薪酬委員會
|
| | | $ | 6,500 | | |
提名和公司治理委員會
|
| | | $ | 4,000 | | |
姓名大於5%
股東(1) |
| |
系列A
可贖回 敞篷車 擇優 庫存 (#)(2) |
| |
系列B-1
可贖回 敞篷車 擇優 庫存 (#)(2) |
| |
B-2系列
可贖回 敞篷車 擇優 庫存 (#)(2) |
| |
B-3系列
可贖回 敞篷車 擇優 庫存 (#)(2) |
| |
系列b-4
可贖回 敞篷車 擇優 庫存 (#)(2) |
| |
B輪
手令(#)(2) |
| |
系列C
可贖回 敞篷車 擇優 庫存 (#)(2) |
| |
系列C
認股權證 (#)(2) |
| |
本金
數額: 橋牌 備註 ($)(2)(3) |
| |||||||||||||||||||||||||||
Bios股權附屬基金
|
| | | | 1,500,000 | | | | | | 1,474,352 | | | | | | 722,167 | | | | | | 862,785 | | | | | | 8,555,060 | | | | | | 136,620 | | | | | | 2,178,894 | | | | | | — | | | | | $ | 5,500,000 | | |
凱羅斯風險投資附屬公司
基金 |
| | | | — | | | | | | 1,904,972 | | | | | | 1,307,093 | | | | | | 639,365 | | | | | | 654,306 | | | | | | 102,468 | | | | | | 133,417 | | | | | | — | | | | | | — | | |
| | |
數量
股份 有益的 擁有 |
| |
受益持股比例
|
| ||||||||||||
實益擁有人姓名或名稱及地址
|
| |
在此之前
供奉 |
| |
之後
供奉 |
| ||||||||||||
董事、董事提名人和被任命的高管
|
| | | | | | | | | | | | | | | | | | |
Daniel·M·施密特(1)
|
| | | | 572,847 | | | | | | 3.72% | | | | | | 2.99% | | |
安德魯·馬紮(2)
|
| | | | 104,422 | | | | | | * | | | | | | * | | |
保羅·萊特爾
|
| | | | — | | | | | | — | | | | | | — | | |
亞倫·GL弗萊徹(3)(4)
|
| | | | 9,628,266 | | | | | | 58.81% | | | | | | 47.95% | | |
託德·湯姆森(5)
|
| | | | 2,680,835 | | | | | | 17.34% | | | | | | 13.99% | | |
小萊斯·克雷斯(4)(6)
|
| | | | 9,620,556 | | | | | | 58.77% | | | | | | 47.91% | | |
丹尼爾·扎布洛夫斯基(7)
|
| | | | 92,290 | | | | | | * | | | | | | * | | |
傑森·凱斯
|
| | | | — | | | | | | — | | | | | | — | | |
艾米·羅恩伯格
|
| | | | — | | | | | | — | | | | | | — | | |
羅傑·索尼
|
| | | | — | | | | | | — | | | | | | — | | |
所有董事、董事提名人和執行官(10人) (8)
|
| | | | 13,249,327 | | | | | | 84.84% | | | | | | 68.56% | | |
5%實益持有人 | | | | | | | | | | | | | | | | | | | |
Bios股權附屬基金(4)
|
| | | | 9,551,181 | | | | | | 58.34% | | | | | | 47.56% | | |
凱羅斯風險投資附屬基金(5)
|
| | | | 2,680,835 | | | | | | 17.34% | | | | | | 13.99% | | |
大約股份數
|
| |
首次公開發售日期
|
|
16,064,383股 | | | 在本招股說明書日期後181天,以下提及的鎖定協議到期時,在某些情況下受規則第144條和規則第701條規定的適用數量、銷售方式和其他限制的限制。 | |
承銷商
|
| |
數
的股份 |
| |||
Titan Partners Group LLC,American Capital Partners,LLC的一個部門
|
| | | | 1,020,000 | | |
新橋證券公司
|
| | | | 1,780,000 | | |
總
|
| | | | 2,800,000 | | |
| | |
每股
|
| |
不含合計
超額配售 選擇權 |
| |
總計(含全部)
超額配售 選擇權 |
| |||||||||
公開發行價
|
| | | $ | 8.00 | | | | | $ | 22,400,000 | | | | | $ | 25,760,000 | | |
承保折扣和佣金(7.0%)
|
| | | $ | 0.56 | | | | | $ | 1,568,000 | | | | | $ | 1,803,200 | | |
扣除費用前的收益,付給我們
|
| | | $ | 7.44 | | | | | $ | 20,832,000 | | | | | $ | 23,956,800 | | |
| | |
頁面
|
| |||
經審計的簡明合併財務報表 | | | | | | | |
| | | | F-2 | | | |
| | | | F-3 | | | |
| | | | F-4 | | | |
| | | | F-5 | | | |
| | | | F-6 | | | |
| | | | F-7 | | | |
未經審計的簡明合併財務報表 | | | | | | | |
| | | | F-25 | | | |
| | | | F-26 | | | |
| | | | F-27 | | | |
| | | | F-28 | | | |
| | | | F-29 | | |
| | |
12月31日,
2023 |
| |
12月31日,
2022 |
| ||||||
資產 | | | | | | | | | | | | | |
流動資產: | | | | | | | | | | | | | |
現金及現金等價物
|
| | | $ | 2,958,659 | | | | | $ | 20,449,310 | | |
預付資產和其他流動資產
|
| | | | 36,907 | | | | | | 33,746 | | |
流動資產總額
|
| | | | 2,995,566 | | | | | | 20,483,056 | | |
總資產
|
| | | $ | 2,995,566 | | | | | $ | 20,483,056 | | |
負債,可贖回可轉換股票
和股東赤字 |
| | | | | | | | | | | | |
流動負債: | | | | | | | | | | | | | |
應付帳款
|
| | | $ | 3,421,840 | | | | | $ | 2,130,847 | | |
應計補償
|
| | | | 277,500 | | | | | | 132,033 | | |
其他應計費用
|
| | | | 3,221,254 | | | | | | 2,082,102 | | |
流動負債總額
|
| | | | 6,920,594 | | | | | | 4,344,982 | | |
長期負債: | | | | | | | | | | | | | |
應計利息
|
| | | | 130,041 | | | | | | 86,400 | | |
認股權證法律責任
|
| | | | 988,049 | | | | | | 814,364 | | |
應付許可證
|
| | | | 404,991 | | | | | | 404,991 | | |
長期負債總額
|
| | | | 1,523,081 | | | | | | 1,305,755 | | |
總負債
|
| | | | 8,443,675 | | | | | | 5,650,737 | | |
承諾和或有事項(注5) | | | | | | | | | | | | | |
可贖回可轉換優先股面值0.00001美元,33,463,018
授權股份;已發行24,678,355股和23,656,337股 分別截至2023年12月31日和2022年12月31日未償還;清算 截至2023年12月31日,價值爲121,033,336美元和108,936,156美元,以及 分別爲2022年。 |
| | | | 94,178,404 | | | | | | 90,137,751 | | |
股東赤字: | | | | | | | | | | | | | |
普通股:面值0.000001美元,授權38,108,584股;已發行和流通股1,690,760股
|
| | | | 2 | | | | | | 2 | | |
額外實收資本
|
| | | | 5,468,006 | | | | | | 5,044,467 | | |
累計赤字
|
| | | | (105,094,521) | | | | | | (80,349,901) | | |
股東總虧損額
|
| | | | (99,626,513) | | | | | | (75,305,432) | | |
負債總額、可贖回可轉換優先股和股東赤字
|
| | | $ | 2,995,566 | | | | | $ | 20,483,056 | | |
| | |
截至的年度
2023年12月31日 |
| |
截至的年度
2022年12月31日 |
| ||||||
運營費用: | | | | | | | | | | | | | |
研發
|
| | | $ | 21,708,332 | | | | | $ | 16,387,216 | | |
一般和行政
|
| | | | 3,265,497 | | | | | | 3,819,591 | | |
總運營費用
|
| | | | 24,973,829 | | | | | | 20,206,807 | | |
運營虧損
|
| | | | (24,973,829) | | | | | | (20,206,807) | | |
其他收入(支出): | | | | | | | | | | | | | |
認購證負債估計公允價值變化
|
| | | | (79,822) | | | | | | 36,579 | | |
利息支出
|
| | | | (43,641) | | | | | | (16,200) | | |
利息收入
|
| | | | 352,672 | | | | | | 27,027 | | |
其他收入合計,淨額
|
| | | | 229,209 | | | | | | 47,406 | | |
淨虧損
|
| | | $ | (24,744,620) | | | | | $ | (20,159,401) | | |
加權平均普通股流通股、基本普通股和稀釋普通股
|
| | | | 1,434,964 | | | | | | 1,210,629 | | |
普通股股東應占每股基本虧損和稀釋後每股淨虧損
|
| | | $ | (17.24) | | | | | $ | (16.65) | | |
| | |
可贖回可兌換
優先股 |
| | |
普通股
|
| |
其他內容
已繳費 資本 |
| |
累計
赤字 |
| |
總
股東的 赤字 |
| |||||||||||||||||||||||||||
| | |
股票
|
| |
金額
|
| | |
股票
|
| |
金額
|
| ||||||||||||||||||||||||||||||
平衡,2022年1月1日
|
| | | | 19,108,155 | | | | | $ | 70,882,182 | | | | | | | 1,718,287 | | | | | $ | 2 | | | | | $ | 4,390,401 | | | | | $ | (60,190,500) | | | | | $ | (55,800,097) | | |
限制性股票獎勵的發放
|
| | | | — | | | | | | — | | | | | | | 104,018 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
取消非歸屬限制性股票獎勵
|
| | | | — | | | | | | — | | | | | | | (131,545) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
基於股票的薪酬費用
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | 654,066 | | | | | | — | | | | | | 654,066 | | |
發行可贖回可轉換優先股的收益,扣除發行成本
|
| | | | 4,548,182 | | | | | | 19,255,569 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
淨虧損
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | (20,159,401) | | | | | | (20,159,401) | | |
餘額,2022年12月31日
|
| | | | 23,656,337 | | | | | | 90,137,751 | | | | | | | 1,690,760 | | | | | | 2 | | | | | | 5,044,467 | | | | | | (80,349,901) | | | | | | (75,305,432) | | |
基於股票的薪酬費用
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | 423,539 | | | | | | — | | | | | | 423,539 | | |
發行可贖回可轉換優先股的收益,扣除發行成本
|
| | | | 1,022,018 | | | | | | 4,134,516 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
與發行可贖回可轉換優先股相關向配股代理發行的認購證的估計公平市場價值
|
| | | | — | | | | | | (93,863) | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
淨虧損
|
| | | | | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | (24,744,620) | | | | | | (24,744,620) | | |
餘額,2023年12月31日
|
| | | | 24,678,355 | | | | | $ | 94,178,404 | | | | | | | 1,690,760 | | | | | $ | 2 | | | | | $ | 5,468,006 | | | | | $ | (105,094,521) | | | | | $ | (99,626,513) | | |
| | |
截至的年度
2023年12月31日 |
| |
截至的年度
2022年12月31日 |
| ||||||
經營活動: | | | | | | | | | | | | | |
淨虧損
|
| | | $ | (24,744,620) | | | | | $ | (20,159,401) | | |
將淨虧損與經營活動中使用的淨現金進行調節的調整:
|
| | | | | | | | | | | | |
基於股票的薪酬費用
|
| | | | 423,539 | | | | | | 654,066 | | |
認購證負債估計公允價值變化
|
| | | | 79,822 | | | | | | (36,579) | | |
應付許可證應計利息
|
| | | | 43,641 | | | | | | 16,200 | | |
經營性資產和負債變動情況:
|
| | | | | | | | | | | | |
預付資產和其他流動資產
|
| | | | (3,161) | | | | | | (25,304) | | |
應付帳款
|
| | | | 1,290,993 | | | | | | 586,259 | | |
應計補償
|
| | | | 145,467 | | | | | | 43,283 | | |
其他應計費用
|
| | | | 1,139,152 | | | | | | 1,127,383 | | |
用於經營活動的現金淨額
|
| | | | (21,625,167) | | | | | | (17,794,093) | | |
融資活動: | | | | | | | | | | | | | |
發行可贖回可轉換優先股所得款項,淨額
|
| | | | 4,134,516 | | | | | | 19,255,569 | | |
融資活動提供的現金淨額
|
| | | | 4,134,516 | | | | | | 19,255,569 | | |
現金和現金等價物淨變化
|
| | | | (17,490,651) | | | | | | 1,461,476 | | |
現金和現金等價物,年初
|
| | | | 20,449,310 | | | | | | 18,987,834 | | |
現金和現金等價物,年終
|
| | | $ | 2,958,659 | | | | | $ | 20,449,310 | | |
補充披露現金流量信息: | | | | | | | | | | | | | |
支付利息的現金
|
| | | $ | — | | | | | $ | — | | |
繳納所得稅的現金
|
| | | $ | — | | | | | $ | — | | |
補充披露非現金融資活動: | | | | | | | | | | | | | |
與發行可贖回可轉換優先股相關向配股代理發行的認購證的估計公平市場價值
|
| | | $ | 93,863 | | | | | $ | — | | |
| | |
2023年12月31日的公允價值計量使用
|
| |||||||||||||||||||||
| | |
公允價值在
12月31日, 2023 |
| |
報價
處於活動狀態 市場: 相同的資產 (一級) |
| |
意義重大
其他 可觀察到的 輸入量 (第二層) |
| |
意義重大
看不見 輸入量 (第三級) |
| ||||||||||||
負債: | | | | | | | | | | | | | | | | | | | | | | | | | |
可贖回可轉換優先股認股權證負債
|
| | | $ | 988,049 | | | | | $ | — | | | | | $ | — | | | | | $ | 988,049 | | |
總負債
|
| | | $ | 988,049 | | | | | $ | — | | | | | $ | — | | | | | $ | 988,049 | | |
| | |
2022年12月31日的公允價值計量使用
|
| |||||||||||||||||||||
| | |
公允價值在
12月31日, 2022 |
| |
報價
處於活動狀態 市場: 相同的資產 (一級) |
| |
意義重大
其他 可觀察到的 輸入量 (第二層) |
| |
意義重大
看不見 輸入量 (第三級) |
| ||||||||||||
負債: | | | | | | | | | | | | | | | | | | | | | | | | | |
可贖回可轉換優先股認股權證負債
|
| | | $ | 814,364 | | | | | $ | — | | | | | $ | — | | | | | $ | 814,364 | | |
總負債
|
| | | $ | 814,364 | | | | | $ | — | | | | | $ | — | | | | | $ | 814,364 | | |
| | |
B系列
可贖回 敞篷車 優先股 認股權證法律責任 |
| |
C系列可贖回
可兌換優先 認股權證 負債 |
| |
總計
|
| |||||||||
截至2022年1月1日的公允價值
|
| | | $ | 850,943 | | | | | $ | — | | | | | $ | 850,943 | | |
公允價值變動
|
| | | | (36,579) | | | | | | — | | | | | | (36,579) | | |
截至2022年12月31日的公允價值
|
| | | | 814,364 | | | | | | — | | | | | | 814,364 | | |
與發行可贖回可轉換優先股相關向配股代理發行的認購證的估計公平市場價值
|
| | | | — | | | | | | 93,863 | | | | | | 93,863 | | |
公允價值變動
|
| | | | 76,691 | | | | | | 3,131 | | | | | | 79,822 | | |
截至2023年12月31日的公允價值
|
| | | $ | 891,055 | | | | | $ | 96,994 | | | | | $ | 988,049 | | |
| | |
2023年12月31日
|
| |
2022年12月31日
|
| ||||||
股票價格
|
| | | $ | 4.78 | | | | | $ | 4.18 | | |
預期期限(三年)
|
| | | | 4.7 | | | | | | 5.7 | | |
預期波動率
|
| | | | 80.68% | | | | | | 82.53% | | |
加權平均無風險利率
|
| | | | 4.48% | | | | | | 3.99% | | |
股息率
|
| | | | 0.00% | | | | | | 0.00% | | |
| | |
2023年12月31日
|
| |
批地日期
|
| ||||||
股票價格
|
| | | $ | 4.72 | | | | | $ | 4.36 | | |
預期期限(三年)
|
| | | | 4.5 | | | | | | 5.0 | | |
預期波動率
|
| | | | 80.68% | | | | | | 83.00 | | |
加權平均無風險利率
|
| | | | 4.48% | | | | | | 4.80% | | |
股息率
|
| | | | 0.00% | | | | | | 0.00% | | |
| | |
2023年12月31日
|
| |
2022年12月31日
|
| ||||||
應計臨床試驗費用
|
| | | $ | 3,207,785 | | | | | $ | 1,895,313 | | |
其他應計費用
|
| | | | 13,469 | | | | | | 186,789 | | |
其他應計費用總額
|
| | | $ | 3,221,254 | | | | | $ | 2,082,102 | | |
| | |
數量
股票 授權 |
| |
數量
股份 已發佈,並 優秀 |
| |
面額
|
| |
清算
價值 |
| |
原創
發行價 |
| |||||||||||||||
系列A
|
| | | | 1,983,663 | | | | | | 1,983,663 | | | | | $ | 3,967,333 | | | | | $ | 6,123,812 | | | | | $ | 2.00000 | | |
系列B-1
|
| | | | 4,133,477 | | | | | | 3,858,547 | | | | | | 14,121,012 | | | | | | 19,401,105 | | | | | $ | 3.65967 | | |
B-2系列
|
| | | | 2,307,017 | | | | | | 2,307,017 | | | | | | 8,824,986 | | | | | | 12,046,258 | | | | | $ | 3.82528 | | |
系列b-3
|
| | | | 1,625,000 | | | | | | 1,625,000 | | | | | | 6,500,000 | | | | | | 8,694,252 | | | | | $ | 4.00000 | | |
系列b-4
|
| | | | 11,961,721 | | | | | | 9,333,928 | | | | | | 39,015,819 | | | | | | 48,356,709 | | | | | $ | 4.18000 | | |
系列C
|
| | | | 11,452,140 | | | | | | 5,570,200 | | | | | | 24,286,072 | | | | | | 26,411,200 | | | | | $ | 4.36000 | | |
| | | | | 33,463,018 | | | | | | 24,678,355 | | | | | $ | 96,715,222 | | | | | $ | 121,033,336 | | | | | | | | |
| | |
數量
股票 授權 |
| |
數量
股份 已發佈,並 優秀 |
| |
面額
|
| |
清算
價值 |
| |
原創
發行價 |
| |||||||||||||||
系列A
|
| | | | 1,983,663 | | | | | | 1,983,663 | | | | | $ | 3,967,333 | | | | | $ | 5,806,426 | | | | | $ | 2.00000 | | |
系列B-1
|
| | | | 4,133,477 | | | | | | 3,858,547 | | | | | | 14,121,012 | | | | | | 18,271,425 | | | | | $ | 3.65967 | | |
B-2系列
|
| | | | 2,307,017 | | | | | | 2,307,017 | | | | | | 8,824,986 | | | | | | 11,340,259 | | | | | $ | 3.82528 | | |
系列b-3
|
| | | | 1,625,000 | | | | | | 1,625,000 | | | | | | 6,500,000 | | | | | | 8,174,252 | | | | | $ | 4.00000 | | |
系列b-4
|
| | | | 11,961,721 | | | | | | 9,333,928 | | | | | | 39,015,819 | | | | | | 45,235,444 | | | | | $ | 4.18000 | | |
系列C
|
| | | | 11,452,140 | | | | | | 4,548,182 | | | | | | 19,830,214 | | | | | | 20,108,350 | | | | | $ | 4.36000 | | |
| | | | | 33,463,018 | | | | | | 23,656,337 | | | | | $ | 92,259,364 | | | | | $ | 108,936,156 | | | | | | | | |
| | |
2023年12月31日
|
| |||
可贖回可轉換優先股的轉換
|
| | | | 13,710,379 | | |
C系列可贖回可轉換優先股證的行使
|
| | | | 18,223 | | |
b系列可贖回可轉換優先股認購證的行使
|
| | | | 152,752 | | |
未償還股票期權
|
| | | | 265,566 | | |
2015年計劃下保留髮行的股份
|
| | | | 624,581 | | |
總計
|
| | | | 14,771,501 | | |
| | |
受限
普通股 獎勵股份 |
| |
加權
平均補助金 公平日期價值 |
| ||||||
2022年1月1日未歸屬餘額
|
| | | | 791,301 | | | | | $ | 2.38 | | |
授與
|
| | | | 104,018 | | | | | $ | 2.11 | | |
既得
|
| | | | (399,255) | | | | | $ | 2.30 | | |
被沒收
|
| | | | (131,545) | | | | | $ | 2.29 | | |
2022年12月31日未歸屬餘額
|
| | | | 364,519 | | | | | $ | 2.23 | | |
授與
|
| | | | — | | | | | $ | — | | |
既得
|
| | | | (195,492) | | | | | $ | 2.23 | | |
被沒收
|
| | | | — | | | | | $ | — | | |
2023年12月31日未歸屬餘額
|
| | | | 169,027 | | | | | $ | 2.21 | | |
| | |
截至的年度
2023年12月31日 |
|
預期波動率
|
| |
82.02%至86.46%
|
|
無風險利率
|
| |
3.90至4.84%
|
|
預期股息收益率
|
| |
0.00%
|
|
預期期限(三年)
|
| |
5.00至5.85
|
|
| | |
數量
股票 |
| |
加權的-
平均值 鍛鍊 價格 |
| |
加權的-
平均值 剩餘 合同 術語(in 年) |
| |
集料
固有的 價值 |
| ||||||||||||
截至2022年12月31日未償還債務
|
| | | | — | | | | | $ | — | | | | | | — | | | | | $ | — | | |
授予的期權
|
| | | | 265,566 | | | | | $ | 2.14 | | | | | | | | | | | | | | |
行使的期權
|
| | | | — | | | | | $ | — | | | | | | | | | | | | | | |
期權被取消並沒收
|
| | | | — | | | | | $ | — | | | | | | | | | | | | | | |
截至2023年12月31日未償還
|
| | | | 265,566 | | | | | $ | 2.14 | | | | | | 9.31 | | | | | $ | 430,210 | | |
已歸屬,預計將於2023年12月31日歸屬
|
| | | | 265,566 | | | | | $ | 2.14 | | | | | | 9.31 | | | | | $ | 430,210 | | |
可於2023年12月31日取消
|
| | | | 47,409 | | | | | $ | 2.14 | | | | | | 9.31 | | | | | $ | 76,802 | | |
| | |
截至的年度
2023年12月31日 |
| |
截至的年度
2022年12月31日 |
| ||||||
研發
|
| | | $ | 129,642 | | | | | $ | 102,853 | | |
一般和行政
|
| | | | 293,897 | | | | | | 551,213 | | |
總計
|
| | | $ | 423,539 | | | | | $ | 654,066 | | |
| | |
截至2013年12月31日止的年度,
|
| |||||||||
| | |
2023
|
| |
2022
|
| ||||||
分子: | | | | | | | | | | | | | |
淨虧損
|
| | | $ | (24,744,620) | | | | | $ | (20,159,401) | | |
分母: | | | | | | | | | | | | | |
已發行普通股的加權平均股數、基本股數和
稀釋 |
| | | | 1,434,964 | | | | | | 1,210,629 | | |
歸屬於普通股股東的每股淨虧損、基本虧損和
稀釋 |
| | | $ | (17.24) | | | | | $ | (16.65) | | |
| | |
截至2013年12月31日,
|
| |||||||||
| | |
2023
|
| |
2022
|
| ||||||
可贖回可轉換優先股
|
| | | | 13,710,379 | | | | | | 13,142,409 | | |
已發行和未執行的期權
|
| | | | 265,566 | | | | | | — | | |
未歸屬的限制性普通股獎勵(「RSA」)
|
| | | | 169,027 | | | | | | 364,519 | | |
購買可贖回可轉換優先股的憑證
|
| | | | 170,975 | | | | | | 152,752 | | |
總計
|
| | | | 14,315,947 | | | | | | 13,659,680 | | |
| | |
12月31日,
2023 |
| |
12月31日,
2022 |
| ||||||
當前 | | | | | | | | | | | | | |
聯邦制
|
| | | $ | — | | | | | $ | — | | |
狀態
|
| | | | — | | | | | | — | | |
外國
|
| | | | — | | | | | | — | | |
總電流
|
| | | | — | | | | | | — | | |
延期 | | | | | | | | | | | | | |
聯邦制
|
| | | | (7,198,732) | | | | | | (7,139,924) | | |
狀態
|
| | | | (92,676) | | | | | | — | | |
外國
|
| | | | — | | | | | | — | | |
更改估值免稅額
|
| | | | 7,291,408 | | | | | | 7,139,924 | | |
延期合計
|
| | | | — | | | | | | — | | |
所得稅撥備(福利)
|
| | | $ | — | | | | | $ | — | | |
| | |
2023年12月31日
|
| |
2022年12月31日
|
| ||||||
遞延所得稅資產(負債): | | | | | | | | | | | | | |
資本化研發,扣除攤銷
|
| | | $ | 6,800,091 | | | | | $ | 3,454,424 | | |
其他
|
| | | | 33,579 | | | | | | 1,050 | | |
淨營業虧損結轉
|
| | | | 12,500,774 | | | | | | 10,875,920 | | |
研發稅收抵免
|
| | | | 12,420,432 | | | | | | 10,132,074 | | |
遞延稅項資產總額
|
| | | | 31,754,875 | | | | | | 24,463,468 | | |
估值免稅額
|
| | | | (31,754,875) | | | | | | (24,463,468) | | |
遞延稅項淨資產
|
| | | $ | — | | | | | $ | — | | |
| | |
2023年12月31日
|
| |
2022年12月31日
|
| ||||||
法定聯邦所得稅率
|
| | | | 21.00% | | | | | | 21.00% | | |
研發稅收抵免
|
| | | | 9.45% | | | | | | 10.96% | | |
其他
|
| | | | (1.32)% | | | | | | 3.91% | | |
更改估值免稅額
|
| | | | (29.13)% | | | | | | (35.87)% | | |
有效所得稅率
|
| | | | 0.00% | | | | | | 0.00% | | |
| | |
3月31日,
2024 |
| |
12月31日,
2023 |
| ||||||
| | |
未經審計
|
| | | | | | | |||
資產 | | | | | | | | | | | | | |
流動資產: | | | | | | | | | | | | | |
現金及現金等價物
|
| | | $ | 2,068,307 | | | | | $ | 2,958,659 | | |
預付資產和其他流動資產
|
| | | | 119,774 | | | | | | 36,907 | | |
流動資產總額
|
| | | | 2,188,081 | | | | | | 2,995,566 | | |
遞延發售成本
|
| | | | 510,502 | | | | | | — | | |
總資產
|
| | | $ | 2,698,583 | | | | | $ | 2,995,566 | | |
負債、可贖回可轉換股票和股東赤字
|
| | | | | | | | | | | | |
流動負債: | | | | | | | | | | | | | |
應付帳款
|
| | | $ | 3,956,063 | | | | | $ | 3,421,840 | | |
應計補償
|
| | | | 277,500 | | | | | | 277,500 | | |
其他應計費用
|
| | | | 5,500,310 | | | | | | 3,221,254 | | |
按公允價值應付的關聯方可轉換票據
|
| | | | 5,000,000 | | | | | | — | | |
流動負債總額
|
| | | | 14,733,873 | | | | | | 6,920,594 | | |
長期負債: | | | | | | | | | | | | | |
應計利息
|
| | | | 135,117 | | | | | | 130,041 | | |
認股權證法律責任
|
| | | | 1,020,564 | | | | | | 988,049 | | |
應付許可證
|
| | | | 404,991 | | | | | | 404,991 | | |
長期負債總額
|
| | | | 1,560,672 | | | | | | 1,523,081 | | |
總負債
|
| | | | 16,294,545 | | | | | | 8,443,675 | | |
承諾和或有事項(注6) | | | | | | | | | | | | | |
可贖回可轉換優先股面值0.00001美元,授權股33,463,018股;已發行和發行股票24,678,355股;截至2024年3月31日和2023年12月31日,清算價值分別爲122,962,342美元和121,033,336美元。
|
| | | | 94,178,404 | | | | | | 94,178,404 | | |
股東赤字: | | | | | | | | | | | | | |
普通股:面值0.000001美元,授權38,108,584股;已發行和流通股1,690,760股
|
| | | | 2 | | | | | | 2 | | |
額外實收資本
|
| | | | 5,616,212 | | | | | | 5,468,006 | | |
累計赤字
|
| | | | (113,390,580) | | | | | | (105,094,521) | | |
股東總虧損額
|
| | | | (107,774,366) | | | | | | (99,626,513) | | |
負債總額、可贖回可轉換優先股和股東赤字
|
| | | $ | 2,698,583 | | | | | $ | 2,995,566 | | |
| | |
截至3月31日的三個月,
|
| |||||||||
| | |
2024
|
| |
2023
|
| ||||||
運營費用: | | | | | | | | | | | | | |
研發
|
| | | $ | 6,860,430 | | | | | $ | 4,523,757 | | |
一般和行政
|
| | | | 912,824 | | | | | | 774,799 | | |
總運營費用
|
| | | | 7,773,254 | | | | | | 5,298,556 | | |
運營虧損
|
| | | | (7,773,254) | | | | | | (5,298,556) | | |
其他收入(支出): | | | | | | | | | | | | | |
認購證負債估計公允價值變化
|
| | | | (32,515) | | | | | | 5,104 | | |
發行按公允價值應付的關聯方可轉換票據損失
|
| | | | (200,000) | | | | | | — | | |
應付關聯方可轉換票據估計公允價值變化
|
| | | | (300,000) | | | | | | — | | |
利息支出
|
| | | | (5,076) | | | | | | (28,454) | | |
利息收入
|
| | | | 14,786 | | | | | | 51,651 | | |
其他收入(費用)合計,淨額
|
| | | | (522,805) | | | | | | 28,301 | | |
淨虧損
|
| | | $ | (8,296,059) | | | | | $ | (5,270,255) | | |
加權平均普通股流通股、基本普通股和稀釋普通股
|
| | | | 1,535,167 | | | | | | 1,339,729 | | |
普通股股東應占每股基本虧損和稀釋後每股淨虧損
|
| | | $ | (5.40) | | | | | $ | (3.93) | | |
| | |
可贖回可兌換
優先股 |
| | |
普通股
|
| |
其他內容
已繳費 資本 |
| |
累計
赤字 |
| |
總
股東的 赤字 |
| |||||||||||||||||||||||||||
| | |
股票
|
| |
金額
|
| | |
股票
|
| |
金額
|
| ||||||||||||||||||||||||||||||
平衡,2024年1月1日
|
| | | | 24,678,355 | | | | | $ | 94,178,404 | | | | | | | 1,690,760 | | | | | $ | 2 | | | | | $ | 5,468,006 | | | | | $ | (105,094,521) | | | | | $ | (99,626,513) | | |
基於股票的薪酬費用
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | 148,206 | | | | | | — | | | | | | 148,206 | | |
淨虧損
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | (8,296,059) | | | | | | (8,296,059) | | |
平衡,2024年3月31日
|
| | | | 24,678,355 | | | | | $ | 94,178,404 | | | | | | | 1,690,760 | | | | | $ | 2 | | | | | $ | 5,616,212 | | | | | $ | (113,390,580) | | | | | $ | (107,774,366) | | |
| | |
可贖回可兌換
優先股 |
| | |
普通股
|
| |
其他內容
已繳費 資本 |
| |
累計
赤字 |
| |
總
股東的 赤字 |
| |||||||||||||||||||||||||||
| | |
股票
|
| |
金額
|
| | |
股票
|
| |
金額
|
| ||||||||||||||||||||||||||||||
平衡,2023年1月1日
|
| | | | 23,656,337 | | | | | $ | 90,137,751 | | | | | | | 1,690,760 | | | | | $ | 2 | | | | | $ | 5,044,467 | | | | | $ | (80,349,901) | | | | | $ | (75,305,432) | | |
基於股票的薪酬費用
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | 73,131 | | | | | | — | | | | | | 73,131 | | |
發行可贖回債券的收益
可轉換優先股,扣除 發行費用206,821美元 |
| | | | 578,037 | | | | | | 2,313,431 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
淨虧損
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | (5,270,255) | | | | | | (5,270,255) | | |
平衡,2023年3月31日
|
| | | | 24,234,374 | | | | | $ | 92,451,182 | | | | | | | 1,690,760 | | | | | $ | 2 | | | | | $ | 5,117,598 | | | | | $ | (85,620,156) | | | | | $ | (80,502,556) | | |
| | |
截至3月31日的三個月,
|
| |||||||||
| | |
2024
|
| |
2023
|
| ||||||
經營活動: | | | | | | | | | | | | | |
淨虧損
|
| | | $ | (8,296,059) | | | | | $ | (5,270,255) | | |
將淨虧損與經營活動中使用的淨現金進行調節的調整:
|
| | | | | | | | | | | | |
基於股票的薪酬費用
|
| | | | 148,206 | | | | | | 73,131 | | |
認購證負債估計公允價值變化
|
| | | | 32,515 | | | | | | (5,104) | | |
發行按公允價值應付的關聯方可轉換票據損失
|
| | | | 200,000 | | | | | | — | | |
應付關聯方可轉換票據估計公允價值變化
|
| | | | 300,000 | | | | | | — | | |
應付許可證應計利息
|
| | | | 5,076 | | | | | | 28,454 | | |
經營性資產和負債變動情況:
|
| | | | | | | | | | | | |
預付資產和其他流動資產
|
| | | | (82,867) | | | | | | 5,245 | | |
應付帳款
|
| | | | 483,703 | | | | | | 468,678 | | |
應計補償
|
| | | | — | | | | | | (132,033) | | |
其他應計費用
|
| | | | 1,961,844 | | | | | | (526,957) | | |
用於經營活動的現金淨額
|
| | | | (5,247,582) | | | | | | (5,358,841) | | |
融資活動: | | | | | | | | | | | | | |
發行應付關聯方可轉換票據所得款項,淨額
|
| | | | 4,500,000 | | | | | | — | | |
即將發行的可贖回可轉換優先股收到的收益
|
| | | | — | | | | | | 150,000 | | |
遞延發售成本
|
| | | | (142,770) | | | | | | — | | |
發行可贖回可轉換優先股所得款項,淨額
|
| | | | — | | | | | | 2,313,431 | | |
融資活動提供的現金淨額
|
| | | | 4,357,230 | | | | | | 2,463,431 | | |
現金和現金等價物淨變化
|
| | | | (890,352) | | | | | | (2,895,410) | | |
期初現金及現金等價物
|
| | | | 2,958,659 | | | | | | 20,449,310 | | |
期末現金和現金等價物
|
| | | $ | 2,068,307 | | | | | $ | 17,553,900 | | |
補充披露現金流量信息: | | | | | | | | | | | | | |
支付利息的現金
|
| | | $ | — | | | | | $ | — | | |
繳納所得稅的現金
|
| | | $ | — | | | | | $ | — | | |
非現金融資活動補充時間表: | | | | | | | | | | | | | |
遞延發行成本,未付和應計
|
| | | $ | 367,732 | | | | | $ | — | | |
| | | | | | | | |
2024年3月31日的公允價值計量使用
|
| |||||||||||||||
| | |
公允價值在
3月31日, 2024 |
| |
報價
處於活動狀態 市場: 相同的資產 (一級) |
| |
重要的其他人
可觀察到的 輸入量 (第二層) |
| |
意義重大
看不見 輸入量 (第三級) |
| ||||||||||||
負債: | | | | | | | | | | | | | | | | | | | | | | | | | |
應付關聯方可轉換票據
|
| | | $ | 5,000,000 | | | | | $ | — | | | | | $ | — | | | | | $ | 5,000,000 | | |
可贖回可轉換優先股認股權證負債
|
| | | | 1,020,564 | | | | | | — | | | | | | — | | | | | | 1,020,564 | | |
總負債
|
| | | $ | 6,020,564 | | | | | $ | — | | | | | $ | — | | | | | $ | 6,020,564 | | |
| | | | | | | | |
2023年12月31日的公允價值計量使用
|
| |||||||||||||||
| | |
公允價值在
12月31日, 2023 |
| |
報價
處於活動狀態 市場: 相同的資產 (一級) |
| |
重要的其他人
可觀察到的 輸入量 (第二層) |
| |
意義重大
看不見 輸入量 (第三級) |
| ||||||||||||
負債: | | | | | | | | | | | | | | | | | | | | | | | | | |
可贖回可轉換優先股認股權證負債
|
| | | $ | 988,049 | | | | | $ | — | | | | | $ | — | | | | | $ | 988,049 | | |
總負債
|
| | | $ | 988,049 | | | | | $ | — | | | | | $ | — | | | | | $ | 988,049 | | |
|
截至2023年12月31日的估計公允價值
|
| | | $ | 988,049 | | |
|
公允價值變動
|
| | | | 32,515 | | |
|
截至2024年3月31日的估計公允價值
|
| | | $ | 1,020,564 | | |
| | |
2024年3月31日
|
| |
2023年12月31日
|
| ||||||
股票價格
|
| | | $ | 4.86 | | | | | $ | 4.78 | | |
預期期限(三年)
|
| | | | 4.4 | | | | | | 4.7 | | |
預期波動率
|
| | | | 83.66% | | | | | | 80.68% | | |
加權平均無風險利率
|
| | | | 5.23% | | | | | | 4.48% | | |
股息率
|
| | | | 0.00% | | | | | | 0.00% | | |
| | |
2024年3月31日
|
| |
2023年12月31日
|
| ||||||
股票價格
|
| | | $ | 4.83 | | | | | $ | 4.72 | | |
預期期限(三年)
|
| | | | 4.2 | | | | | | 4.5 | | |
預期波動率
|
| | | | 83.84% | | | | | | 80.68% | | |
加權平均無風險利率
|
| | | | 5.23% | | | | | | 4.48% | | |
股息率
|
| | | | 0.00% | | | | | | 0.00% | | |
|
發行時的估計公允價值
|
| | | $ | 4,700,000 | | |
|
公允價值變動
|
| | | | 300,000 | | |
|
截至2024年3月31日的估計公允價值
|
| | | $ | 5,000,000 | | |
| | |
2024年3月31日
|
| |
2023年12月31日
|
| ||||||
應計臨床試驗費用
|
| | | $ | 5,170,182 | | | | | $ | 3,207,785 | | |
其他應計費用
|
| | | | 330,128 | | | | | | 13,469 | | |
其他應計費用總額
|
| | | $ | 5,500,310 | | | | | $ | 3,221,254 | | |
| | |
數量
股份 授權 |
| |
數量
股份 已發佈,並 優秀 |
| |
臉
金額 |
| |
清算
價值 |
| |
原創
發行價 |
| |||||||||||||||
系列A
|
| | | | 1,983,663 | | | | | | 1,983,663 | | | | | $ | 3,967,333 | | | | | $ | 6,202,941 | | | | | $ | 2.00000 | | |
系列B-1
|
| | | | 4,133,477 | | | | | | 3,858,547 | | | | | | 14,121,012 | | | | | | 19,682,752 | | | | | $ | 3.65967 | | |
B-2系列
|
| | | | 2,307,017 | | | | | | 2,307,017 | | | | | | 8,824,986 | | | | | | 12,222,274 | | | | | $ | 3.82528 | | |
系列b-3
|
| | | | 1,625,000 | | | | | | 1,625,000 | | | | | | 6,500,000 | | | | | | 8,823,896 | | | | | $ | 4.00000 | | |
系列b-4
|
| | | | 11,961,721 | | | | | | 9,333,928 | | | | | | 39,015,819 | | | | | | 49,134,888 | | | | | $ | 4.18000 | | |
系列C
|
| | | | 11,452,140 | | | | | | 5,570,200 | | | | | | 24,286,072 | | | | | | 26,895,591 | | | | | $ | 4.36000 | | |
| | | | | 33,463,018 | | | | | | 24,678,355 | | | | | $ | 96,715,222 | | | | | $ | 122,962,342 | | | | | | | | |
| | |
數量
股份 授權 |
| |
數量
股份 已發佈,並 優秀 |
| |
臉
金額 |
| |
清算
價值 |
| |
原創
發行價 |
| |||||||||||||||
系列A
|
| | | | 1,983,663 | | | | | | 1,983,663 | | | | | $ | 3,967,333 | | | | | $ | 6,123,812 | | | | | $ | 2.00000 | | |
系列B-1
|
| | | | 4,133,477 | | | | | | 3,858,547 | | | | | | 14,121,012 | | | | | | 19,401,105 | | | | | $ | 3.65967 | | |
B-2系列
|
| | | | 2,307,017 | | | | | | 2,307,017 | | | | | | 8,824,986 | | | | | | 12,046,258 | | | | | $ | 3.82528 | | |
系列b-3
|
| | | | 1,625,000 | | | | | | 1,625,000 | | | | | | 6,500,000 | | | | | | 8,694,252 | | | | | $ | 4.00000 | | |
系列b-4
|
| | | | 11,961,721 | | | | | | 9,333,928 | | | | | | 39,015,819 | | | | | | 48,356,709 | | | | | $ | 4.18000 | | |
系列C
|
| | | | 11,452,140 | | | | | | 5,570,200 | | | | | | 24,286,072 | | | | | | 26,411,200 | | | | | $ | 4.36000 | | |
| | | | | 33,463,018 | | | | | | 24,678,355 | | | | | $ | 96,715,222 | | | | | $ | 121,033,336 | | | | | | | | |
| | |
2024年3月31日
|
| |||
可贖回可轉換優先股的轉換
|
| | | | 13,710,379 | | |
應付關聯方可轉換票據的轉換
|
| | | | 576,475 | | |
C系列可贖回可轉換優先股證的行使
|
| | | | 18,223 | | |
b系列可贖回可轉換優先股認購證的行使
|
| | | | 152,752 | | |
未償還股票期權
|
| | | | 393,346 | | |
2015年計劃下保留髮行的股份
|
| | | | 496,801 | | |
總計
|
| | | | 15,347,976 | | |
| | |
受限
普通股 獎勵股份 |
| |
加權
平均補助金 公平日期價值 |
| ||||||
2023年12月31日未歸屬餘額
|
| | | | 169,027 | | | | | $ | 2.21 | | |
授與
|
| | | | — | | | | | $ | — | | |
既得
|
| | | | (30,642) | | | | | $ | 2.11 | | |
被沒收
|
| | | | — | | | | | $ | — | | |
2024年3月31日未歸屬餘額
|
| | | | 138,385 | | | | | $ | 2.23 | | |
| | |
截至三個月
2024年3月31日 |
| |||
預期波動率
|
| | | | 81.65% | | |
無風險利率
|
| | | | 4.23% | | |
預期股息收益率
|
| | | | 0.00% | | |
預期期限(三年)
|
| | | | 5.85 | | |
| | |
數
的 股票 |
| |
加權的-
平均值 鍛鍊 價格 |
| |
加權的-
平均值 剩餘 合同 任期(年) |
| |
集料
固有的 價值 |
| ||||||||||||
截至2023年12月31日未償還
|
| | | | 265,566 | | | | | $ | 2.14 | | | | | | 9.31 | | | | | | | | |
授予的期權
|
| | | | 127,780 | | | | | $ | 4.68 | | | | | | | | | | | | | | |
行使的期權
|
| | | | — | | | | | $ | — | | | | | | | | | | | | | | |
期權被取消並沒收
|
| | | | — | | | | | $ | — | | | | | | | | | | | | | | |
截至2024年3月31日未償還
|
| | | | 393,346 | | | | | $ | 2.97 | | | | | | 9.34 | | | | | $ | 1,346,606 | | |
已歸屬,預計將於2024年3月31日歸屬
|
| | | | 393,346 | | | | | $ | 2.97 | | | | | | 9.34 | | | | | $ | 1,346,606 | | |
可於2024年3月31日取消
|
| | | | 87,452 | | | | | $ | 2.14 | | | | | | 8.98 | | | | | $ | 371,497 | | |
| | |
截至3月31日的三個月,
|
| |||||||||
| | |
2024
|
| |
2023
|
| ||||||
研發
|
| | | $ | 72,948 | | | | | $ | 15,621 | | |
一般和行政
|
| | | | 75,258 | | | | | | 57,510 | | |
總計
|
| | | $ | 148,206 | | | | | $ | 73,131 | | |
| | |
截至3月31日的三個月,
|
| |||||||||
| | |
2024
|
| |
2023
|
| ||||||
分子: | | | | | | | | | | | | | |
淨虧損
|
| | | $ | (8,296,059) | | | | | $ | (5,270,255) | | |
分母: | | | | | | | | | | | | | |
加權平均普通股流通股、基本普通股和稀釋普通股
|
| | | | 1,535,167 | | | | | | 1,339,729 | | |
普通股股東應占每股基本虧損和稀釋後每股淨虧損
|
| | | $ | (5.40) | | | | | $ | (3.93) | | |
| | |
3月31日,
|
| |||||||||
| | |
2024
|
| |
2023
|
| ||||||
可贖回可轉換優先股
|
| | | | 13,710,379 | | | | | | 13,463,542 | | |
用於購買可贖回可轉換優先股的關聯方可轉換票據
|
| | | | 576,475 | | | | | | — | | |
已發行和未執行的期權
|
| | | | 393,346 | | | | | | — | | |
未歸屬的限制性普通股獎勵(「RSA」)
|
| | | | 138,385 | | | | | | 303,203 | | |
購買可贖回可轉換優先股的憑證
|
| | | | 170,975 | | | | | | 152,752 | | |
總計
|
| | | | 14,989,560 | | | | | | 13,919,497 | | |